The optimal multidisciplinary treatment strategies for patients receiving radiation treatments are evolving in the era of precision medicine. Moreover, it is increasingly evident that the genetic composition of tumors affects radiation treatment sensitivity. This activity will review salient genetic biomarkers that impact the treatments of cancer patients with radiation.
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Identify best practice genetic biomarkers testing across common cancer types.
- Indicate optimal treatment recommendations on the basis of genetically-stratified populations.
- Recognize state-of-the-art new biomarker studies that are likely to change practice.
Mohamed Abazeed, MD, PhD is employed by Northwestern University and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.